Compare Honeywell International Inc (HON) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Neurocrine Biosciences Inc — how do they compare? Honeywell International Inc trades at $206.7 (market cap $65.96B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Honeywell International Inc is far larger — about 4.5× Neurocrine Biosciences Inc's market cap, and Honeywell International Inc pays a 1.35% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 90 Days and Neurocrine Biosciences Inc for 23 Days on average.
| HON | NBIX | |
|---|---|---|
Market Cap | $65.96B | $14.60B |
Volume | 2,009,898 | 1,075,694 |
Sector | Industrials | Health |
52-Week High | $248.79 | $185.50 |
52-Week Low | $188.14 | $123.10 |
Typical Hold Time | 90 Days | 23 Days |
Enterprise Value | $90.75B | $14.61B |
Dividend Yield | 1.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $206.6, down 2.95% on the day, with a bearish technical signal despite strong fundamentals including a low P/E of 8 and robust profitability margins. Recent quarterly earnings have consistently beaten expectations, and the company secured a significant $300 million refinery project with Dangote. Analyst consensus remains strongly bullish with a $259.25 price target, representing 25% upside potential from current levels.
The stock presents a compelling value opportunity given its discounted valuation metrics and consistent earnings outperformance, though investors face near-term technical headwinds and execution risks from the company's recent strategic transformation into a pure-play automation business following the spin-off of its aerospace and advanced materials divisions.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
